Nicotine chewing gum has become the most popular nicotine replacement product worldwide. It provides an instant, self-controllable effect, and it is discreet and easy to administer 'on the go', complying perfectly with modern life style.
An increasing number of smokers want to quit smoking. Nicotine replacement therapy (NRT) can double the chances of quitting successfully and has been shown to be safe and effective in helping people reduce or stop smoking.
The worldwide market potential for Nicotine chewing gum is huge and today sales are only established in North America, Western Europe, Japan and Australia. Significant new sales are forseen in the coming years when smokers in Asia, Eastern Europe, Russia and Latin America will start to use NRT products to quit or reduce smoking. Several Global trends accelerate the market growth:
Fertin Pharma is the world-leading B2B partner in nicotine chewing gum.
We have unique competencies that fulfils user demands and our production meets the highest of standards:
Partnering with Fertin Pharma is the proven way to success in NRT
The time frame for developing a new NRT gum is less than two years. From laboratory phase and upscaling to process validation, consumer tests, BE study, stability and registration file.
Interested in learning more about NRT?
Please call Bjarne C Pedersen, Director Business Development
P. +45 41 32 93 25
E. bcp@fertin.com
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
